Gray C M, Schapiro J M, Winters M A, Merigan T C
Center for AIDS Research at Stanford, Division of Infectious Disease and Geographic Medicine, Stanford University School of Medicine, California 94305, USA.
AIDS Res Hum Retroviruses. 1998 May 1;14(7):561-9. doi: 10.1089/aid.1998.14.561.
This study explores whether previous failures on antiretroviral drug regimens preclude the possibility of immune restoration. This was assessed by evaluating T cell subset changes in individuals who received a salvage regimen of highly active antiretroviral therapy (HAART) after initially failing protease inhibitor monotherapy. Ten HIV-1-infected asymptomatic patients received a regimen of indinavir, zidovudine, and 3TC after failing saquinavir monotherapy. Changes in absolute numbers of naive, memory, and activated CD4+ and CD8+ T cells expressing a selection of CD45RA, CD62L, CD45RO, HLA-DR, and CD38 markers were monitored prospectively over 6 months. These measurements were correlated with plasma viral load along with alterations in a selected CD8+ V alpha/Vbeta T cell receptor (TCR) repertoire. Over 6 months there was a progressive increase in numbers of CD4+ memory (CD45RA-CD62L+) and naive (CD45RA+CD62L+) T cells, which displayed a modest inverse correlation with viral load. Two phases of CD8+ memory cell changes were identified, consisting of a transient increase in CD45RA+CD62L- numbers after 2 months and thereafter a progressive rise in CD45RA-CD62L+ cells until 6 months. A strong correlation existed between reduced viral load and loss of activated CD8+CD38+HLA-DR+ cell numbers. There was also a temporary broadening of the CD8+ V alpha/Vbeta TCR repertoire at 8 weeks, which became skewed after 6 months in parallel with reduced viral suppression. Closer analysis of naive and memory cell subset proportions in individual patients revealed that enlarged pools of naive subsets were evident in those patients with rebounds in viral load. Overall, drug-experienced patients responding to HAART displayed increased numbers of naive and memory CD4+ subsets, and reduced CD8+ cell activation with a loss of TCR skewing.
本研究探讨既往抗逆转录病毒药物治疗失败是否会排除免疫恢复的可能性。通过评估最初蛋白酶抑制剂单药治疗失败后接受高效抗逆转录病毒治疗(HAART)挽救方案的个体的T细胞亚群变化来进行评估。10名HIV-1感染的无症状患者在沙奎那韦单药治疗失败后接受了茚地那韦、齐多夫定和拉米夫定的治疗方案。对表达一系列CD45RA、CD62L、CD45RO、HLA-DR和CD38标志物的初始、记忆和活化CD4+和CD8+T细胞的绝对数量变化进行了为期6个月的前瞻性监测。这些测量结果与血浆病毒载量以及选定的CD8+Vα/VβT细胞受体(TCR)库的变化相关。在6个月内,CD4+记忆(CD45RA-CD62L+)和初始(CD45RA+CD62L+)T细胞数量逐渐增加,与病毒载量呈适度负相关。确定了CD8+记忆细胞变化的两个阶段,包括2个月后CD45RA+CD62L-数量短暂增加,此后CD45RA-CD62L+细胞逐渐增加直至6个月。病毒载量降低与活化的CD8+CD38+HLA-DR+细胞数量减少之间存在强相关性。在8周时CD8+Vα/VβTCR库也有暂时拓宽,6个月后随着病毒抑制作用减弱而变得偏斜。对个体患者初始和记忆细胞亚群比例的进一步分析显示,病毒载量反弹的患者中初始亚群库扩大明显。总体而言,对HAART有反应的有药物治疗经验的患者初始和记忆CD4+亚群数量增加,CD8+细胞活化减少,TCR偏斜消失。